Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Executive Summary New Phase 3 data have been published for lonvo-z. As a result, MARA has placed the asset under structured surveillance reassessment. The current MARA Rating for lonvo-z remains
Lilly to Acquire Ajax Therapeutics in Pursuit of Improved JAK Inhibitor Summary Lilly announced on Monday that it will acquire biotech startup Ajax Therapeutics for up to $2.3 billion. The
UCB Expands Into Regenerative Medicine with $1.2B Acquisition of Neurona Therapeutics Summary Belgian drug company UCB has announced its acquisition of Neurona Therapeutics for $650 million upfront, with the potential
Summary Gilead Sciences has announced its acquisition of German biotechnology startup Tubulis for $3.15 billion upfront and a potential additional $1.85 billion based on milestones. This deal expands Gilead’s portfolio
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug White House seeks 12% cut to HHS in 2027 Summary The White House has proposed a 12% cut to the Department of Health
SummaryEli Lilly and Company has announced its acquisition of Centessa Pharmaceuticals, a company focused on developing treatments for rare diseases and neurodegenerative disorders. The deal, valued at $6.3 billion,
Summary Biogen, a major biopharmaceutical company, has announced its plans to acquire Apellis Pharmaceuticals for $5.6 billion. This deal will expand Biogen’s presence in the immunology market, adding a new
Summary Blackstone, a leading private equity firm, has announced the closure of a new $6.3 billion fund dedicated to investing in the life sciences sector. The fund, named Blackstone Life
Novartis acquires Excellergy, a startup focused on developing allergy treatments, in hopes of finding a successor to their current drug Xolair. The deal, worth up to $280 million, includes an
Summary Merck has announced its plans to acquire Terns Pharmaceuticals for $6.7 billion, in a move to bolster its oncology portfolio. The deal includes Terns’ lead drug candidate, TRN-823, which